Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus ORGATRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus ORGATRAX.
HISTAFED vs ORGATRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
ORGATRAX (letermovir) inhibits the cytomegalovirus (CMV) DNA terminase complex, preventing viral DNA processing and packaging.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
Hydroxyzine pamoate (Orgatrax) 25-100 mg orally every 6-8 hours as needed; maximum 600 mg/day.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal elimination half-life is 6–8 hours in adults with normal renal and hepatic function. In elderly patients or those with hepatic impairment, half-life may be prolonged up to 12–15 hours, requiring dose adjustment.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Primarily hepatic metabolism with renal excretion of metabolites. Approximately 30% of a dose is excreted unchanged in urine; the remainder is eliminated via feces (biliary excretion) after glucuronidation in the liver.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine